Truist Financial Raises the PT on Pediatrix Medical (MD), Keeps a Buy

​Pediatrix Medical Group, Inc. (NYSE:MD) is one of the Hottest Small Cap Stocks to Buy Now. On November 10, David S Macdonald from Truist Financial raised the firm’s price target on Pediatrix Medical Group, Inc. (NYSE:MD) from $17 to $24, while reiterating a Buy rating.

​The enhanced positive outlook follows a 33.59% increase in share price since the company released its fiscal Q3 2025 results on November 3. The company delivered $492.88 million in quarterly revenue, down 3.58% year-over-year, but surpassing analysts’ estimates by $16.43 million. The EPS of $0.67 also topped the consensus by $0.20.

​Management attributed the decrease in revenue to its portfolio restructuring activity of approximately $54 million. However, the decrease was offset by 8% growth in same-unit, 7.5% increase in same-unit pricing, and around 40 basis points increase in patient service volumes.

​In addition, the adjusted EBITDA for the quarter reached $87 million, exceeding management’s expectations. This was driven by positive pricing outcomes, collections, and expense controls. As a result, Pediatrix Medical Group, Inc. (NYSE:MD) raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million, up from the previous guidance range of $245 million to $255 million.

​Pediatrix Medical Group, Inc. (NYSE:MD) is a leading provider of specialized physician services for women, babies, and children, focusing on newborn, maternal-fetal, and pediatric subspecialty care.

While we acknowledge the potential of MD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.